Pathology of Parkinson's disease - Changes other than the nigrostriatal pathway

Molecular and Chemical Neuropathology

Volumn 14, Issue 3, 1991, Pages 153-197

  Jellinger, Kurt A ^a  

^a GENERAL HOSPITAL LINZ   (Austria)

Author keywords

degeneration; morphometry; neurochemistry; neuropathology; Parkinson's disease; subcortical systems

Indexed keywords

ACETYLCHOLINE; DOPAMINE; NEUROPEPTIDE; NORADRENALIN; SEROTONIN;

ADULT; AGED; CLINICAL ARTICLE; CORPUS STRIATUM; DEMENTIA; FEMALE; HUMAN; HUMAN TISSUE; MALE; MORPHOMETRICS; PARKINSON DISEASE; REVIEW; SUBSTANTIA NIGRA;

ACETYLCHOLINE; AGING; BRAIN; DOPAMINE; HUMAN; NEURAL PATHWAYS; NEUROPEPTIDES; NOREPINEPHRINE; PARKINSON DISEASE; SEROTONIN;

EID: 0026348872     PISSN: 10447393     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03159935     Document Type: Article

References (263)

1. Biochemistry of neurotransmitters in Parkinson’s disease
2. The efficacy of levodopa treatment declines in the course of Parkinson’s disease: Do nondopaminergic lesions play a role?
3. Chronic administration of MPTP to marmosets
4. The functional anatomy of basal ganglia disorders
5. Parallel organization of functionally segregated circuits linking basal ganglia and cortex
6. Dissociation of NPY and somatostatin in Parkinson disease
7. Neuropeptides and dopamine in the marmoset—Effect of treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): An animal model for Parkinson’s disease
8. Morphometric immunochemical analysis of neurons in the nucleus basalis of Meynert in Alzheimer’s disease
9. Changes of biogenic amines and their metabolites in postmortem brains from patients with Alzheimer type dementia
10. Somatostatin and vasoactive intestinal polypeptide in postmortem brains from patients with Alzheimer type dementia
11. Neuronal loss in different parts of the nucleus basalis is related to neuritic plaque formation in cortical area in Alzheimer’s disease
12. Loss of neurons in the nucleus basalis of Meynert in Alzheimer’s disease, paralysis agitans and Korsakoff’s disease
13. Amyloid deposition in the nucleus basalis of Meynert complex: A topographic marker for degenerating cell clusters in Alzheimer’s disease
14. Dendritic changes in the nucleus basalis of Menyert and in the diagonal band nucleus in Alzheimer’s disease. A quantitative Golgi investigation
15. Substance P and somatostatin coexist within neuritic plaques: Implications for the pathogenesis of Alzheimer’s disease
16. Antigenic profile of Lewy bodies: Immunocytochemical evidence for protein phosphorylation and ubiquitination
17. Neuropeptides in neurological disease
18. Somatostatin and neuropeptide Y immunoreactivity in Parkinson’s disease dementia with Alzheimer’s changes
19. Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer’s disease
20. Somatostatin receptors are reduced in cerebral cortex in Alzheimer’s disease
21. Striatal substance P cell clusters coincide with the high density terminal zones of the discontinuous nigrostriatal dopaminergic projection system in the cat
22. Brain control of conjugate horizontal and vertical eye movements
23. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical morphological and neurochemical correlations
24. The cholinergic system in aging
25. Biological aspects of depression in Parkinson’s disease
26. Alterations in regional brain concentrations of neurotensin and bombesin in Parkinson’s disease
27. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics
28. Loss of neurons of origin of the adrenergic projections to the cerebral cortex (nucleus locus ceruleus) in senile dementia
29. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease
30. Treatment of Alzheimer’s disease
31. Astrocytes as a primary locus for the conversion of MPTP into MPP+
32. Evidence for retrograde degeneration of epinephrine neurons in Alzheimer’s disease
33. Pathological changes in the nucleus basalis of Meynert in Alzheimer’s and Parkinson’s disease
34. Somatostatin immunoreactivity in cortical and some subcortical regions in Alzheimer’s disease
35. Decreased catecholamines in the adrenal medulla of patients with parkinsonism
36. Parkinson’s disease and dementia: Norepinephrine and dopamine in locus ceruleus
37. Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/silver intensification on vibratome sections: Coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia
38. Cortical neurons immunoreactive with antisera against neuropeptide Y are altered in Alzheimer’s type dementia
39. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression
40. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of Alzheimer type and in Parkinson’s disease with and without dementia and depression
41. Distribution of altered hippocampal neurons and axons immunoreactive with antisera against Neuropeptide Y in Alzheimer’s type dementia
42. Coexistence of somatostatin and neuropeptide Y in the hippocampus of patients with Alzheimer’s and Parkinson’s disease
43. Neurotensin receptors in Parkinson’s disease and progressive supranuclear palsy: An autoradiographic study in basal ganglia
44. Pathological correlates of dementia in Parkinson’s disease
45. The mesencephalic centre controlling locomotion in the rat
46. Neuropeptides in Alzheimer’s and in Parkinson’s disease
47. Serotonin receptor changes in dementia of the Alzheimer type
48. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides
49. Nucleus raphe dorsalis in dementia of the Alzheimer type: neurofibrillary changes and neuronal packing density
50. Aminergic systems in Alzheimer’s disease and Parkinson’s disease
51. Neurochemical studies: An update on Alzheimer’s disease
52. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease
53. Parkinsonism secondary to intravenous injection of meperidine analogues
54. Decreased somatostatin immunoreactivity but not neuropeptide Y immunoreactivity in cerebral cortex in dementia of Alzheimer type
55. Diffuse Lewy body disease: Light and electron microscopic immunocytochemistry of senile plaques
56. On the distribution of cholecystokinin receptor binding sites in the human brain. An autoradiographic study
57. Cell loss from the nucleus basalis of Meynert in Alzheimer disease
58. Cholinergic deficiency and frontal dysfunction in Parkinson’s disease
59. Démence et maladie de Parkinson: Correlations biochimiques et anatomo-cliniques
60. The pathology of certain medullary nuclei in parkinsonism
61. Somatostatin in the central nervous system: Physiology and pathological modifications
62. Somatostatin concentrations and binding sites in human frontal cortex are differently affected in Parkinson’s disease associated with dementia and supranuclear palsy
63. Somatostatin and dementia in Parkinson’s disease
64. A quantitative study of the neurofibrillary tangles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer’s disease
65. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer’s disease
66. The nucleus basalis of Meynert
67. Peptides in the neocortex in Alzheimer’s disease and aging
68. Nucleus locus ceruleus: New evidence of anatomical and physiological specificity
69. The Lewy body in Parkinson’s disease
70. Ultrastructure of the neostriatum in Huntington’s and Parkinson’s disease
71. Somatostatin-like immunoreactivity in the human basal ganglia (abstract)
72. An electron microscopic study of MPTP-induced inclusion bodies in old monkey
73. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys
74. Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer’s disease
75. Tacrine, a drug with therapeutic potential for dementia: Postmortem biochemical evidence
76. Somatostatin content and release measured in cerebral biopsies from demented patients
77. Dementia in idiopathic Parkinson’s disease. A neuropathological study of 32 cases
78. Somatostatin 28 and neuropeptide Y innervation in the septal area and related cortical and subcortical structures of the human brain. Distribution, relationship and evidence for different coexistence
79. 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced parkinsonian syndrome, in Macaca fascicularis: Which midbrain dopaminergic neurons are lost?
80. Midbrain catecholaminergic loss in Parkinson’s disease: Computer visualization
81. The human locus coeruleus: Computer reconstruction of cellular distribution
82. Alzheimer’s disease: Neurofibrillary tangles in nuclei that project to the cerebral cortex
83. The septo-hippocampal pathway in patients suffering from dementia of Alzheimer’s type. Evidence for neuronal plasticity?
84. Cortical cholinergic fibers in aging and Alzheimer’s disease: A morphometric study
85. The anatomy and pigmentation of the human substania nigra in relation to selective neuronal vulnerability
86. The substantia nigra and ventral tegmental areas in Alzheimer’s disease and Down’s syndrome
87. The evolution of morphological changes in the nervous system of the common marmoset following the acute administration of MPTP
88. Role of striatonigral substance P in the regulation of activity of the striatonigral dopaminergic neurones
89. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson’s disease and striatonigral degeneration
90. Immunohistochemical study of the striatal efferents and nigral dopaminergic neurons in parkinsonism-dementia complex on Guam in comparison with those in Parkinson’s and Alzheimer’s diseases
91. The supraoptic and paraventricular nuclei of the human hypothalamus in relation to sex, and Alzheimer’s disease
92. Substance P and met-enkephalin immunoreactivity in Parkinson’s, Huntington’s and Alzheimer’s disease
93. Neuropeptides in the basal ganglia
94. Dopaminergic and cholinergic systems in the striatum
95. The nigrostriatal system in Parkinson’s disease
96. Reversible supranuclear ophthalmoplegia associated with parkinsonism
97. Loss of brainstem serotonin- and substance P-containing neurons in Parkinson’s disease
98. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson’s disease
99. Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain
100. The origins of cholinergic and other subcortical afferents to the thalamus in the rat
101. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus
102. Topography of the magnocellular basal forebrain system in human brain
103. Dementia without Alzheimer pathology
104. Is Alzheimer’s disease an anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells?
105. Melanized dopaminergic neurons are differently susceptible to degeneration in Parkinson’s disease
106. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson’s disease and progressive supranuclear palsy
107. Coexistence of peptides with classical neurotransmitters
108. Parkinson’s disease and its chemotherapy
109. The neurochemical basis of the pharmacology of Parkinson’s disease
110. Biochemical changes in idiopathic, Parkinson’s disease, aging, and MPTP parkinsonism: Similarities and differences
111. The rostral mesencephalon in Parkinson’s and Alzheimer’s disease
112. Morphological and biochemical changes in the cholinergic and monoaminergic system in Alzheimer-type dementia
113. The organization of divergent axonal projections from the midbrain raphe nuclei in the rat
114. The locus coeruleus: Computer assisted 3-dimensional analysis of degeneration in Alzheimer’s and Down’s disease
115. Decreased tysosine hydroxylase messenger RNA in the surviving dopamine neurons of the substantia nigra in Parkinson’s disease: An in situ hybridization study
116. Microtopography of tyrosine hydroxylase, glutamic adic decarboxylase and choline acetyltransferase in the substantia nigra and ventral tegmental area of control and parkinsonian brain
117. Biochemical neuropathology of Parkinson’s disease
118. Overview of morphological changes in Parkinson’s disease
119. The pathology of parkinsonism
120. The pedunculopontine nucleus in Parkinson’s disease, supranuclear palsy and Alzheimer’s disease
121. Pathology of Parkinson’s syndrome
122. Changes in subcortical nuclei in Parkinson’s disease
123. New developments in the pathology of Parkinson’s disease
124. Morphology of Alzheimer’s disease and related disorders
125. Bedeutung der Nigraveränderungen bei Parkinson-Syndromen
126. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): An update on its relevance to the cause and treatment of Parkinson’s disease
127. Mesencephalic cholinergic nuclei in progressive supranuclear palsy
128. Clinical, pathological, and neurochemical changes in dementia: A subgroup with preserved mental status and numerous cortical plaques
129. Corticotropin-releasing factor immunoreactive neurons persist throughout the brain in Alzheimer’s disease
130. Uneven patterns of dopamine loss in the striatum of patients with Parkinson’s disease
131. Colocalization of neuropeptide tyrosine and somatostatin immunoreactivity in neurons of individual hippocampal subfields in rat
132. Topographic immunocytochemical mapping of monoamine oxidase A, monoamine oxidase B and tyrosine hydroxylase in human postmortem brain stem
133. MPTP in animal models of Parkinson’s disease
134. Autonomic nervous system screening in patients with early Parkinson’s disease
135. Cortical somatostatin, neuropeptide Y, and NADPH diaphorase neurons: Normal anatomy and alterations in Alzheimer’s disease
136. Innervation of substance P neurons by catecholaminergic terminals in the neostriatum
137. Pyridine toxins
138. Zur pathologischen Anatomie der Paralysis agitans
139. Dopaminergic regulation of tachykinin metabolism in the striatonigral pathway
140. Enkephalinergic markers in substantia nigra and caudate nucleus from parkinsonian subjects
141. Efferent projections of nucleus locus coeruleus: Topographic organization of cells of origin demonstrated by three-dimensional reconstruction
142. The basal nucleus of Meynert revisited
143. Biochemical neuroanatomy of the basal ganglia
144. Aging, Alzheimer’s disease, and the cholinergic system in the basal forebrain
145. Catecholaminergic systems in the medulla oblongata in Parkinsonian syndromes. A quantitative immunohistochemical study in Parkinson’s disease, progressive supranuclear palsy, and striatonigral degeneration
146. Decrease of serotonin-R-2 receptors in temporal cortex of patients with Parkinson’s disease and progressive supranuclear palsy
147. Pathological basis for neurotransmitter changes in Parkinson’s disease
148. Neurotransmitter deficits in Alzheimer’s disease and other dementing disorders
149. The pathology of the human locus coeruleus
150. Changes in nerve cells of the nucleus basalis of Meynert in Alzheimer’s disease and their relationship to the accumulation of lipofuscin pigment
151. Correlation between senile plaques and neurofibrillary tangle counts in the cerebral cortex and neuron al counts in cortex and subcortical structures in Alzheimer’s disease
152. Changes in Alzheimer’s disease in the magnocellular neurons of the supraoptic and paraventricular nuclei and their relationship to the noradrenergic deficit
153. Dopaminergic systems in Alzheimer’s disease and Down’s syndrome at middle age
154. Loss of nerve cells from locus coeruleus in Alzheimer’s disease is topographically arranged
155. The topography of nerve cell loss from the locus coeruleus in elderly persons
156. The nucleus basalis of Menyert in Parkinson-dementia of Guam: A morphometric study
157. Preservation of hypothalamic dopaminergic neurons in Parkinson’s disease
158. Decrease of substance P-like immunoreactivity in the substantia nigra and palidum of parkinsonian brains
159. The “serotonin hypothesis” for depression in Parkinson’s disease
160. Serotonergic dysfunction in depression
161. Nucleus basalis (Ch4) and cortical cholinergic innervation in the human brain: Observations based on the distribution of acetylcholinesterase and choline acetyltransferase
162. Neuronal inputs into the nucleus basalis of the substantia innominata (Ch4) in the rhesus monkey
163. Basal ganglia function in experimental movement disorders
164. Bilateral symmetry of morphologic lesions in Alzheimer’s disease
165. Neurofibrillary tangles in cholinergic pedunculopontine nucleus in Alzheimer’s disease
166. Nerve growth factor immunoreactivity with the nucleus basalis (Hc 4) in Parkinson disease. Reduced cell numbers and co-localization with cholinergic neurons
167. Serotonergic innervation of the cat cerebral cortex
168. Changes of tyrosine hydroxylase in parkinsonian brains and in the brains of MPTP treated mice
169. Neuron loss in the nucleus basalis of Meynert in Parkinson-dementia complex of Guam
170. Tyrosine hydroxylase proteins in Lewy bodies of parkinsonism and senile brain
171. Neuropeptides in Alzheimer’s disease: A postmortem study
172. Catecholaminergic neurons assessed ante-mortem in Alzheimer’s disease
173. Anterograde vs retrograde degeneration of the nucleus basalis medialis in Alzheimer’s disease
174. Persistence of cholinergic neurons in the basal nucleus of a brain with senile dementia of the Alzheimer’s type
175. Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types
176. Nicotinic (3H-nicotine) receptor binding in human brain: Characterization and involvement in cholinergic neuropathology
177. Cholinergic correlates of cognitive impairment in Parkinson’s disease: Comparison with Alzheimer’s disease
178. Neuropathological and biochemical observations on the noradrenergic system in Alzheimer’s disease
179. Alzheimer’s disease: Recent advances in neuropathology
180. Senile dementia of Lewy body type: A clinically and neuropathologically distinct form of Lewy body dementia in the elderly
181. Cortical cholinergic deficit in mentally impaired Parkinsonian patients
182. Cortical neuropathological and neurochemical substrates of Alzheimer’s and Parkinson’s disease
183. Differential modification of muscarinic cholinergic receptors in the hippocampus of patients with Alzheimer’s disease: An autoradiographic study
184. Neurotransmitter and receptor deficits in senile dementia of the Alzheimer type
185. Choline acetyltransferase-like immunoreactivity in the hippocampal formation of control subjects and patients with Alzheimer’s disease
186. Abnormal ocular movements in Parkinson’s disease
187. Striatonigral GABA dynorphin, substance P and neurokinin-A modulation of nigrostriatal release. Evidence for direct regulatory mechanisms
188. A postmortem study of noradrenergic, serotonergic and GABAergic neurones in Alzheimer’s disease
189. Cholinergic deficit in Alzheimer’s disease: A study based on CSF and autopsy data
190. Aging and MPTP-induced degeneration of dopaminergic neurons in the substantia nigra
191. CNS modulation of adrenal tyrosine hydroxylase in Parkinson’s disease and metabolic encephalopathies
192. The role of dopamine in the control of neurobiological functions
193. Neuronal size and density in the nucleus basalis Meynert in Alzheimer’s disease
194. Brain muscarinic receptor subtypes are differentially affected in Alzheimer’s disease and Parkinson’s disease
195. Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra
196. Brain enkephalin receptors in Parkinson’s disease
197. The nucleus basalis Meynert in neurological disease: A quantitative morphological study
198. Neurochemical characteristics of early and late onset types of Alzheimer’s disease
199. Dementia in Parkinson’s disease
200. Dopaminergic and cholinergic lesions in progressive supranuclear palsy
201. Loss of high affinity neurotensin receptors in substantia nigra from parkinsonian subjects
202. Neuronal pathology in the nucleus basalis of Meynert and associated cell groups in senile dementia of the Alzheimer’s type. Possible role in cell loss
203. The organization of the nucleus tegmenti pedunculopontine neurons projecting to basal ganglia and thalamus
204. Degeneration of noradrenergic and serotonergic but not dopaminergic neurons in lumbar spinal cord of parkinsonian patients
205. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP
206. Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson’s disease
207. Monoaminerge Läsion bei seniler Demenz vom Alzheimer-Typ (SDAT)
208. Alzheimer’s disease. Aminergic-cholinergic alterations in hypothalamus
209. Serotonin-immunoreactive neurons and their projections in the CNS
210. Cholecystokinin octapeptide immunoreactivity distribution in human brain
211. Normal hippocampal circuitry
212. A quantitative and ultrastructural study of substantia nigra and nucleus centralis superior in Alzheimer’s disease
213. Dynorphin levels in parkinsonian patients
214. Levels of MET-Enkephalin, LEU-Enkephalin, Substance P and Cholecystokinin in the Brain of the Common Marmoset Following Long Term 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Treatment
215. Substance P immunoreactivity in post-mortem parkinsonian brain
216. Brain substance P receptors in Parkinson’s disease
217. Structure-function correlations in Alzheimer’s disease (abstract)
218. The neuropathology of Alzheimer’s disease—issues in need of resolution
219. Cell loss in the locus coeruleus in senile dementia of the Alzheimer type
220. Neuropathology of the locus coeruleus: A semiquantitative study
221. Mesocorticolimbical dementia
222. The association of ventral tegmental area histopathology with adult dementia
223. Parkinson’s disease: Loss of neurons from the ventral tegmental area contralateral to therapeutic surgical lesions
224. Dementia pugilistica: Loss of basal forebrain cholinergic neurons and cortical cholinergic markers
225. Altered lipofuscin pigmentation in the basal nucleus (Meynert) in Parkinson’s disease
226. Mesolimbicocortical dementia: Clinico-pathological studies on two cases
227. A quantitative study of pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging
228. Neuronal hypertrophy in the human supraoptic and paraventricular nucleus in aging and Alzheimer’s disease
229. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer’s disease
230. Parkinson’s disease: The presence of Lewy bodies in Auerbach’s and Meissner’s plexuses
231. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson’s disease and Huntington’s chora
232. Distinct monoamine oxidase A and B populations in primate brain
233. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem
234. Ocular motor deficits in Parkinson’s disease. I and II
235. Basal forebrain neurons in the dementia of Parkinson’s disease
236. Reductions in corticotropin releasing factor-like immunoreactivity in cerebral cortex in Alzheimer’s disease, Parkinson’s disease and progressive supranuclear palsy
237. Reductions in [3H]nicotinic acetylcholine binding in Alzheimer’s disease and Parkinson’s disease: An autoradiographic study
238. Cortical somatostatinergic system not affected in Alzheimer’s and Parkinson’s diseases
239. The differential involvement of subcortical nuclei in senile dementia of the Alzheimer type
240. Parameters of cholinergic neurotransmission in the thalamus in Parkinson’s disease and Alzheimer’s disease
241. Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbinding D 28K
242. Nucleus raphe dorsalis in Parkinson’s dementia complex of Guam
243. Neurotensin immunoreactivity in post-mortem brain is increased in Down’s syndrome but not in Alzheimer-type dementia
244. Methionine, enkephalin and substance P in the basal ganglia of schizophrenics: A quantitative immunohistochemical comparison with Huntington and Parkinson patients
245. Neurochemical correlates of major depression in primary dementia
246. Bilateral symmetry of cholinergic deficits in Alzheimer’s disease
247. The pedunculopontine nucleus in Parkinson’s disease
248. The neuropathology of aminergic nuclei in Alzheimer’s disease
249. The locus ceruleus and dementia in Parkinson’s disease and Huntington’s disease
250. Neuropathology of aminergic nuclei in Alzheimer’s disease